Skip to main content

Advertisement

SpringerLink
Log in

Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?

  • Review
  • Published:
Naunyn-Schmiedeberg's Archives of Pharmacology Aims and scope Submit manuscript

Abstract

Cystic fibrosis (CF) is the most common genetic disease among Caucasians and is caused by mutations in the CF transmembrane conductance regulator (CFTR) gene. CF affects multiple organs but lung disease is the major determinant for morbidity and mortality. Many studies have focussed on the correlation between CFTR genotype and severity of disease. Since patients with identical CFTR mutations often show considerable variability in disease progression, genes other than CFTR are thought to have the potential to modify the course of lung disease in CF patients. Therefore, identification of CF-modifying genes has become the goal of several studies over the last 15 years. Pharmaceutical approaches for CF lung disease have been developed regardless of the underlying genetic defect and in general target symptoms such as airway obstruction and treatment of bacterial infection. Analysing the pathophysiological processes of modifiers may lead to the discovery of pathways involved in CF pathophysiology and possibly to the design of new therapeutics. The purpose of this review is not only to list potential CFTR modifier genes, but also to discuss new therapeutic strategies that could be derived from knowledge of these CF modifiers.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  • Abraham LJ, Kroeger KM (1999) Impact of the −308 TNF promoter polymorphism on the transcriptional regulation of the TNF gene: relevance to disease. J Leukoc Biol 66:562–566

    PubMed  CAS  Google Scholar 

  • Arkwright PD, Laurie S, Super M, Pravica V, Schwarz MJ, Webb AK, Hutchinson IV (2000) TGF-beta(1) genotype and accelerated decline in lung function of patients with cystic fibrosis. Thorax 55:459–462

    Article  PubMed  CAS  Google Scholar 

  • Arkwright PD, Pravica V, Geraghty PJ, Super M, Webb AK, Schwarz M, Hutchinson IV (2003) End-organ dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med 167:384–389

    Article  PubMed  Google Scholar 

  • Awad MR, El-Gamel A, Hasleton P, Turner DM, Sinnott PJ, Hutchinson IV (1998) Genotypic variation in the transforming growth factor-beta1 gene: association with transforming growth factor-beta1 production, fibrotic lung disease, and graft fibrosis after lung transplantation. Transplantation 66:1014–1020

    Article  PubMed  CAS  Google Scholar 

  • Balfour-Lynn IM, Laverty A, Dinwiddie R (1996) Reduced upper airway nitric oxide in cystic fibrosis. Arch Dis Child 75:319–322

    PubMed  CAS  Google Scholar 

  • Baranov VS, Ivaschenko T, Bakay B, Aseev M, Belotserkovskaya R, Baranova H, Malet P, Perriot J, Mouraire P, Baskakov VN, Savitskyi GA, Gorbushin S, Deyneka SI, Michnin E, Barchuck A, Vakharlovsky V, Pavlov G, Shilko VI, Guembitzkaya T, Kovaleva L (1996) Proportion of the GSTM1 0/0 genotype in some Slavic populations and its correlation with cystic fibrosis and some multifactorial diseases. Hum Genet 97:516–520

    Article  PubMed  CAS  Google Scholar 

  • Baranova H, Perriot J, Albuisson E, Ivaschenko T, Baranov VS, Hemery B, Mouraire P, Riol N, Malet P (1997) Peculiarities of the GSTM1 0/0 genotype in French heavy smokers with various types of chronic bronchitis. Hum Genet 99:822–826

    Article  PubMed  CAS  Google Scholar 

  • Belvisi MG, Stretton CD, Yacoub M, Barnes PJ (1992) Nitric oxide is the endogenous neurotransmitter of bronchodilator nerves in humans. Eur J Pharmacol 210:221–222

    Article  PubMed  CAS  Google Scholar 

  • Bonfield TL, Panuska JR, Konstan MW, Hilliard KA, Hilliard JB, Ghnaim H, Berger M (1995) Inflammatory cytokines in cystic fibrosis lungs. Am J Respir Crit Care Med 152:2111–2118

    PubMed  CAS  Google Scholar 

  • Bowden A, Morton M, Stevens L, Tomkinson A, Tepper J (2006) Effect of the serine protease inhibitor AER 002 on epithelial sodium channel activitiy: a novel treatment for CF and COPD. Proc Am Thorac Soc [abstract] 3:A717

    Google Scholar 

  • Brennan AL, Geddes DM (2004) Bringing new treatments to the bedside in cystic fibrosis. Pediatr Pulmonol 37:87–98

    Article  PubMed  Google Scholar 

  • Brinkman BM, Zuijdeest D, Kaijzel EL, Breedveld FC, Verweij CL (1995–1996) Relevance of the tumor necrosis factor alpha (TNF alpha) −308 promoter polymorphism in TNF alpha gene regulation. J Inflamm 46:32–41

    Google Scholar 

  • Brouard J, Knauer N, Boelle PY, Corvol H, Henrion-Caude A, Flamant C, Bremont F, Delaisi B, Duhamel JF, Marguet C, Roussey M, Miesch MC, Chadelat K, Boule M, Fauroux B, Ratjen F, Grasemann H, Clement A (2005) Influence of interleukin-10 onAspergillus fumigatus infection in patients with cystic fibrosis. J Infect Dis 191:1988–1991

    Article  PubMed  CAS  Google Scholar 

  • Brown RK, Kelly FJ (1994) Role of free radicals in the pathogenesis of cystic fibrosis. Thorax 49:738–742

    PubMed  CAS  Google Scholar 

  • Büscher R, Herrmann V, Insel PA (1999) Human adrenoceptor polymorphisms: evolving recognition of clinical importance. Trends Pharmacol Sci 20:94–99

    Article  PubMed  Google Scholar 

  • Büscher R, Eilmes KJ, Grasemann H, Torres B, Knauer N, Sroka K, Insel PA, Ratjen F (2002) β2 adrenoceptor gene polymorphisms in cystic fibrosis lung disease. Pharmacogenetics 12:347–353

    Article  PubMed  Google Scholar 

  • Büscher R, Hoerning A, Patel HH, Zhang S, Arthur DB, Grasemann H, Ratjen F, Insel PA (2006) P2Y2 receptor polymorphisms and haplotypes in cystic fibrosis and their impact on Ca2+ influx. Pharmacogenetics and Genomics 16:199–205

    PubMed  Google Scholar 

  • Burnett D, McGillivray DH, Stockley RA (1984) Evidence that alveolar macrophages can synthesize and secrete alpha 1-antichymotrypsin. Am Rev Respir Dis 129:473–476

    PubMed  CAS  Google Scholar 

  • Cantin AM, North SL, Hubbard RC, Crystal RG (1987) Normal alveolar epithelial lining fluid contains high levels of glutathione. J Appl Physiol 63:152–157

    PubMed  CAS  Google Scholar 

  • Carlsson M, Sjoholm AG, Eriksson L, Thiel S, Jensenius JC, Segelmark M, Truedsson L (2005) Deficiency of the mannan-binding lectin pathway of complement and poor outcome in cystic fibrosis: bacterial colonization may be decisive for a relationship. Clin Exp Immunol 139:306–313

    Article  PubMed  CAS  Google Scholar 

  • Celedon JC, Lange C, Raby BA, Litonjua AA, Palmer LJ, DeMeo DL, Reilly JJ, Kwiatkowski DJ, Chapman HA, Laird N, Sylvia JS, Hernandez M, Speizer FE, Weiss ST, Silverman EK (2004) The transforming growth factor-beta1 (TGFB1) gene is associated with chronic obstructive pulmonary disease (COPD). Hum Mol Genet 13:1649–1656

    Article  PubMed  CAS  Google Scholar 

  • Cenci E, Mencacci A, Fe d’Ostiani C et al (1998) Cytokine- and T helper-dependent lung mucosal immunity in mice with invasive pulmonary aspergillosis. J Infect Dis 178:1750–1760

    Article  PubMed  CAS  Google Scholar 

  • Chmiel JF, Kostan MW, Knesebeck JE, Hilliard JB, Bonfield TL, Dawson DV, Berger M (1999) IL-10 attenuates excessive inflammation in chronic Pseudomonas infection in mice. Am J Respir Crit Care Med 160:2040–2047

    PubMed  CAS  Google Scholar 

  • Chmiel JF, Konstan MW, Saadane A, Krenicky JE, Kirchner HL, Berger M (2002) Prolonged inflammatory response to acute Pseudomonas challenge in interleukin-10 knockout mice. Am J Respir Crit Care Med 165:1176–1181

    PubMed  Google Scholar 

  • Choi EH, Ehrmantraut M, Foster CB, Moss J, Chanock SJ (2006) Association of common haplotypes of surfactant protein A1 and A2 (SFTPA1 and SFTPA2) genes with severity of lung disease in cystic fibrosis. Pediatr Pulmonol 41:255–262

    Article  PubMed  Google Scholar 

  • Colombo JL (2003) Long-acting bronchodilators in cystic fibrosis. Curr Opin Pulm Med 9:504–508

    Article  PubMed  Google Scholar 

  • Colp C, Pappas J, Moran D, Lieberman J (1993) Variants of alpha 1-antitrypsin in Puerto Rican children with asthma. Chest 103:812–815

    PubMed  CAS  Google Scholar 

  • Davies JC, Griesenbach U, Alton E (2005) Modifier genes in cystic fibrosis. Pediatr Pulmonol 39:383–391

    Article  PubMed  CAS  Google Scholar 

  • Deterding R, Retsch-Bogart G, Milgram L, Gibson R, Daines C, Zeitlin PL, Milla C, Marshall B, LaVange L, Engels J, Mathews D, Gorden J, Schaberg A, Williams J, Ramsey B (2005) Safety and tolerability of denufosol tetrasodium inhalation solution, a novel P2Y2 receptor agonist: results of a phase 1/phase 2 multicenter study in mild to moderate cystic fibrosis. Pediatr Pulmonol 39:339–348

    Article  PubMed  Google Scholar 

  • Dorfman R, Sandford A, Markiewicz D, Master A, Deng G, Patel M, Corey M, Yuan X, Tan M, Li F, Frangolias D, Sun L, Pare P, Durie P, Tsui L, Zielenski J, Zielenski C (2004) Analysis of candidate genes as modifiers of cystic fibrosis. Pediatr Pulmonol Suppl 27:220–221

    Google Scholar 

  • Dorfman R, Sandford A, Corey M, Markiewicz D, Yuan X, Master A, Inna E, Sang Y, Lin F, Wang V, Taylor C, Breaton J, Christofi M, Rousseau R, van Spall M, Aznarez I, Berthiaume Y, Pare P, Tsui L, Durie P, Zielenski J (2005) Canadian CF modifier gene project: the current status. Pediatr Pulmonol Suppl 28:248–249

    Google Scholar 

  • Döring G, Krogh-Johansen H, Weidinger S, Hoiby N (1994) Allotypes of alpha 1-antitrypsin in patients with cystic fibrosis, homozygous and heterozygous for deltaF508. Pediatr Pulmonol 18:3–7

    PubMed  Google Scholar 

  • Drumm ML, Konstan MW, Schluchter MD, Handler A, Pace R, Zou F, Zariwala M, Fargo D, Xu A, Dunn JM, Darrah RJ, Dorfman R, Sandford AJ, Corey M, Zielenski J, Durie P, Goddard K, Yankaskas JR, Wright FA, Knowles MR; Gene Modifier Study Group (2005) Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med 353:1443–1453

    Article  PubMed  CAS  Google Scholar 

  • Dunning AM, Ellis PD, McBride S, Kirschenlohr HL, Healey CS, Kemp PR, Luben RN, Chang-Claude J, Mannermaa A, Kataja V, Pharoah PD, Easton DF, Ponder BA, Metcalfe JC (2003) A transforming growth factor beta1 signal peptide variant increases secretion in vitro and is associated with increased incidence of invasive breast cancer. Cancer Res 63:2610–2615

    PubMed  CAS  Google Scholar 

  • Dupuy PM, Shore SA, Drazen JM, Frostell C, Hill WA, Zapol WM (1992) Bronchodilator action of inhaled nitric oxide in guinea pigs. J Clin Invest 90:421–428

    PubMed  CAS  Google Scholar 

  • El-Gamel A, Awad M, Sim E, Hasleton P, Yonan N, Egan J, Deiraniya A, Hutchinson IV (1998) Transforming growth factor-beta1 and lung allograft fibrosis. Eur J Cardiothorac Surg 13:424–430

    Article  PubMed  CAS  Google Scholar 

  • Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, Belousova EG, Xuan W, Bye PT; National Hypertonic Saline in Cystic Fibrosis (NHSCF) Study Group (2006) A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354:229–240

    Article  PubMed  CAS  Google Scholar 

  • Eriksson S (1965) Studies in alpha 1-antitrypsin deficiency. Acta Med Scand 432:1–85

    CAS  Google Scholar 

  • Fang FC (1997) Perspectives series: host/pathogen interactions. Mechanisms of nitric oxide-related antimicrobial activity. J Clin Invest 99:2818–2825

    PubMed  CAS  Google Scholar 

  • Feldman RD, Fick RB, McArdle W, Lai CC (1987) Are lymphocyte beta-adrenoceptors altered in patients with cystic fibrosis? Clin Sci 73:407–410

    PubMed  CAS  Google Scholar 

  • Flamant C, Henrion-Caude A, Boelle PY, Bremont F, Brouard J, Delaisi B, Duhamel JF, Marguet C, Roussey M, Miesch MC, Boule M, Strange RC, Clement A (2004) Glutathione-S-transferase M1, M3, P1 and T1 polymorphisms and severity of lung disease in children with cystic fibrosis. Pharmacogenetics 14:295–301

    Article  PubMed  CAS  Google Scholar 

  • Frangolias DD, Ruan J, Wilcox PJ, Davidson AG, Wong LT, Berthiaume Y, Hennessey R, Freitag A, Pedder L, Corey M, Sweezey N, Zielenski J, Tullis E, Sandford AJ (2003) Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol 29:390–396

    Article  PubMed  CAS  Google Scholar 

  • Fryer AA, Bianco A, Hepple M, Jones PW, Strange RC, Spiteri MA (2000) Polymorphism at the glutathione S-transferase GSTP1 locus. A new marker for bronchial hyperresponsiveness and asthma. Am J Respir Crit Care Med 161:1437–1442

    PubMed  CAS  Google Scholar 

  • Gabolde M, Guilloud-Bataille M, Feingold J, Besmond C (1999) Association of variant alleles of mannose binding lectin with severity of pulmonary disease in cystic fibrosis: cohort study. BMJ 319:1166–1167

    PubMed  CAS  Google Scholar 

  • Garred P, Madsen HO, Svejgaard A (1996) Genetics of human mannose-binding protein. In: Ezekowitz RA, Sastry K, Reid KBM (eds) Collectins and innate immunity. Landes, Austin, TX, pp 139–164

    Google Scholar 

  • Garred P, Pressler T, Madsen HO, Frederiksen B, Svejgaard A, Hoiby N, Schwartz M, Koch C (1999) Association of mannose-binding lectin gene heterogeneity with severity of lung disease and survival in cystic fibrosis. J Clin Invest 104:431–437

    PubMed  CAS  Google Scholar 

  • Garred P, Pressler T, Lanng S, Madsen HO, Moser C, Laursen I, Balstrup F, Koch C, Koch C (2002) Mannose-binding lectin (MBL) therapy in an MBL-deficient patient with severe cystic fibrosis lung disease. Pediatr Pulmonol 33:201–207

    Article  PubMed  Google Scholar 

  • Goldstein W, Döring G (1986) Lysosomal enzymes and proteinase inhibitors in the sputum of patients with cystic fibrosis. Am Rev Respir Dis 134:49–56

    PubMed  CAS  Google Scholar 

  • Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, Carter ND, Spector TD (1999) Genetic control of the circulating concentration of transforming growth factor type beta1. Hum Mol Genet 8:93–97

    Article  PubMed  CAS  Google Scholar 

  • Grasemann H, Ratjen F (1999) Cystic fibrosis lung disease: the role of nitric oxide. Pediatr Pulmonol 28:442–448

    Article  PubMed  CAS  Google Scholar 

  • Grasemann H, Michler E, Wallot M, Ratjen F (1997) Decreased concentration of exhaled nitric oxide (NO) in patients with cystic fibrosis. Pediatr Pulmonol 24:173–177

    Article  PubMed  CAS  Google Scholar 

  • Grasemann H, Ioannidis I, Tomkiewicz RP, de Groot H, Rubin BK, Ratjen F (1998) Nitric oxide metabolites in cystic fibrosis lung disease. Arch Dis Child 78:49–53

    PubMed  CAS  Google Scholar 

  • Grasemann H, Gärtig SS, Wiesemann HG, Teschler H, Konietzko N, Ratjen F (1999) Effect ofl-arginine infusion on airway NO in cystic fibrosis and primary ciliary dyskinesia syndrome. Eur Respir J 13:114–118

    Article  PubMed  CAS  Google Scholar 

  • Grasemann H, Knauer N, Büscher R, Hübner K, Drazen JM, Ratjen F (2000) Airway nitric oxide levels in cystic fibrosis patients are related to a polymorphism in the neuronal nitric oxide synthase gene. Am J Respir Crit Care Med 162:2172–2176

    PubMed  CAS  Google Scholar 

  • Grasemann H, Storm van’s Gravesande K, Gärtig S, Kirsch M, Büscher R, Drazen JM, Ratjen F (2002) Nasal nitric oxide levels are associated with a polymorphism in the neuronal nitric oxide synthase (NOS1) genes in cystic fibrosis patients. Nitric Oxide 6:236–241

    Article  PubMed  CAS  Google Scholar 

  • Grasemann H, Storm van’s Gravesande K, Büscher R, Drazen JM, Ratjen F (2003a) Effects of sex and of gene variants in constitutive nitric oxide synthases on exhaled nitric oxide. Am J Respir Crit Care Med 167:1113–1116

    Article  PubMed  Google Scholar 

  • Grasemann H, Storm van’s Gravesande K, Büscher R, Knauer N, Silverman ES, Palmer LJ, Drazen JM, Ratjen F (2003b) Endothelial nitric oxide synthase variants in cystic fibrosis lung disease. Am J Respir Crit Care Med 167:390–394

    Article  PubMed  Google Scholar 

  • Grasemann H, Lax H, Treseler JW, Colin AA (2004) Dornase alpha and exhaled NO in cystic fibrosis. Pediatr Pulmonol 38:379–385

    Article  PubMed  Google Scholar 

  • Grasemann H, Schwiertz R, Matthiesen S, Racke K, Ratjen F (2005a) Increased arginase activity in cystic fibrosis airways. Am J Respir Crit Care Med 172:1523–1528

    Article  PubMed  Google Scholar 

  • Grasemann H, Grasemann C, Kurtz F, Tietze-Schillings G, Vester U, Ratjen F (2005b) Oral l-arginine supplementation in cystic fibrosis patients: a placebo-controlled study. Eur Respir J 25:62–68

    Article  PubMed  CAS  Google Scholar 

  • Grasemann H, Schwiertz R, Grasemann C, Vester U, Racke K, Ratjen F (2006a) Decreased systemic bioavailability of l-arginine in patients with cystic fibrosis. Respir Res 7:87

    Article  PubMed  CAS  Google Scholar 

  • Grasemann H, Kurtz F, Ratjen F (2006b) Inhaled l-arginine improves exhaled nitric oxide and pulmonary function in cystic fibrosis patients. Am J Respir Crit Care Med 174:208–212

    Article  PubMed  CAS  Google Scholar 

  • Greally P, Hussein MJ, Cook AJ, Sampson AP, Piper PJ, Price JF (1993) Sputum tumour necrosis factor-alpha and leukotriene concentrations in cystic fibrosis. Arch Dis Child 68:389–392

    PubMed  CAS  Google Scholar 

  • Griese M, von Bredow C, Birrer P, Scharms A (2001) Inhalation of α1-protease inhibitor in cystic fibrosis does not affect surfactant convertase and surface activity. Pulmonol Pharmacol Ther 14:461–467

    Article  CAS  Google Scholar 

  • Guggino WB, Banks-Schlegel SP (2004) Macromolecular interactions and ion transport in cystic fibrosis. Am J Respir Crit Care Med 170:815–820

    Article  PubMed  Google Scholar 

  • Harrison DJ, Cantlay AM, Rae F, Lamb D, Smith CA (1997) Frequency of glutathione S-transferase M1 deletion in smokers with emphysema and lung cancer. Hum Exp Toxicol 16:356–360

    PubMed  CAS  Google Scholar 

  • Hart MA, Konstan MW, Darrah RJ, Schluchter MD, Storfer-Isser A, Xue L, Londono D, Goddard KA, Drumm ML (2005) Beta 2 adrenergic receptor polymorphisms in cystic fibrosis. Pediatr Pulmonol 39:544–550

    Article  PubMed  Google Scholar 

  • Hayes JD, Strange RC (2000) Glutathione S-transferase polymorphisms and their biological consequences. Pharmacology 61:154–166

    Article  PubMed  CAS  Google Scholar 

  • Henrion-Caude A, Flamant C, Roussey M, Housset C, Flahault A, Fryer AA, Chadelat K, Strange RC, Clement A (2002) Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology 36:913–917

    PubMed  CAS  Google Scholar 

  • Henry MT, Cave S, Rendall J, O’Connor CM, Morgan K, FitzGerald MX, Kalsheker N (2001) An alpha1-antitrypsin enhancer polymorphism is a genetic modifier of pulmonary outcome in cystic fibrosis. Eur J Hum Genet 9:273–278

    Article  PubMed  CAS  Google Scholar 

  • Ho LP, Innes JA, Greening AP (1998) Exhaled nitric oxide is not elevated in the inflammatory airways diseases of cystic fibrosis and bronchiectasis. Eur Respir J 12:1290–1294

    Article  PubMed  CAS  Google Scholar 

  • Hull J, Thomson AH (1998) Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Throax 53:1018–1021

    CAS  Google Scholar 

  • Hull J, Vervaart P, Grimwood K, Phelan P (1997) Pulmonary oxidative stress response in young children with cystic fibrosis. Thorax 52:557–560

    PubMed  CAS  Google Scholar 

  • Ignotz R, Massague J (1986) Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. J Biol Chem 261:4337–4345

    PubMed  CAS  Google Scholar 

  • Insel PA (1996) Seminars in medicine of the Beth Israel Hospital, Boston. Adrenergic receptors-evolving concepts and clinical implications. N Engl J Med 334:580–585

    Article  PubMed  CAS  Google Scholar 

  • Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, Cooper DM, Fahy JV, Fish JE, Ford JG, Kraft M, Kunselman S, Lazarus SC, Lemanske RF, Martin RJ, McLean DE, Peters SP, Silverman EK, Sorkness CA, Szefler SJ, Weiss ST, Yandava CN (2000) The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 162:75–80

    PubMed  CAS  Google Scholar 

  • Kellerman D, Evans R, Mathews D, Shaffer C (2002) Inhaled P2Y2 receptor agonists as a treatment for patients with Cystic Fibrosis lung disease. Adv Drug Deliv Rev 54:1463–1474

    Article  PubMed  CAS  Google Scholar 

  • Kerem E, Corey M, Kerem BS, Rommens J, Markiewicz D, Levison H, Tsui LC, Durie P (1990) The relation between genotype and phenotype in cystic fibrosis—analysis of the most common mutation (delta F508). N Engl J Med 323:1517–1522

    Article  PubMed  CAS  Google Scholar 

  • King MA, Stone JA, Diaz PT, Mueller CF, Becker WJ, Gadek JE (1996) Alpha 1-antitrypsin deficiency: evaluation of bronchiectasis with CT. Radiology 199:137–141

    PubMed  CAS  Google Scholar 

  • Knauer N, Ratjen F, Grasemann H (2005) Cystic fibrosis modifying genes. Pneumologie 59:309–404

    Article  Google Scholar 

  • Kobayashi M, Nasuhara Y, Kamachi A, Tanino Y, Betsuyaku T, Yamaguchi E, Nishihira J, Nishimura M (2006) Role of macrophage migration inhibitory factor in ovalbumin-induced airway inflammation in rats. Eur Respir J 2:726–734

    Article  CAS  Google Scholar 

  • Kroeger KM, Carville KS, Abraham LJ (1997) The −308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 34:391–399

    Article  PubMed  CAS  Google Scholar 

  • Kunzelmann K, Mall M (2003) Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics. Am J Respir Med 2:299–309

    PubMed  CAS  Google Scholar 

  • Leineweber K, Büscher R, Bruck H, Brodde OE (2004) Beta-adrenoceptor polymorphisms. Naunyn Schmiedebergs Arch Pharmacol 369:1–22

    Article  PubMed  CAS  Google Scholar 

  • Lester LA, Kraut J, Lloyd-Still J, Karrison T, Mott C, Billstrand C, Lemke A, Ober C (1994) Delta F508 genotype does not predict disease severity in an ethnically diverse cystic fibrosis population. Pediatrics 93:114–118

    PubMed  CAS  Google Scholar 

  • Liggett SB (2000) The pharmacogenetics of beta2-adrenergic receptors: relevance to asthma. J Allergy Clin Immunol 105:S487–S492

    Article  PubMed  CAS  Google Scholar 

  • Madsen HO, Garred P, Kurtzhals JA, Lamm LU, Ryder LP, Thiel S, Svejgaard A (1994) A new frequent allele is the missing link in the structural polymorphism of the human mannan-binding protein. Immunogenetics 40:37–44

    Article  PubMed  CAS  Google Scholar 

  • Mahadeva R, Westerbeek RC, Perry DJ, Lovegrove JU, Whitehouse DB, Carroll NR, Ross-Russell RI, Webb AK, Bilton D, Lomas DA (1998a) Alpha1-antitrypsin deficiency alleles and the Taq-I G->A allele in cystic fibrosis lung disease. Eur Respir J 11:873–879

    Article  CAS  Google Scholar 

  • Mahadeva R, Stewart S, Bilton D, Lomas DA (1998b) Alpha-1 antitrypsin deficiency alleles and severe cystic fibrosis lung disease. Thorax 53:1022–1024

    Article  CAS  Google Scholar 

  • Mahadeva R, Sharples L, Ross-Russell RI, Webb AK, Bilton D, Lomas DA (2001) Association of alpha (1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis. Thorax 56:53–58

    Article  PubMed  CAS  Google Scholar 

  • Mann CL, Davies MB, Boggild MD, Alldersea J, Fryer AA, Jones PW, Ko Ko C, Young C, Strange RC, Hawkins CP (2000) Glutathione S-transferase polymorphisms in MS: their relationship to disability. Neurology 54:552–557

    PubMed  CAS  Google Scholar 

  • Mattey DL, Hassell AB, Plant M, Dawes PT, Ollier WR, Jones PW, Fryer AA, Alldersea JE, Strange RC (1999) Association of polymorphism in glutathione S-transferase loci with susceptibility and outcome in rheumatoid arthritis: comparison with the shared epitope. Ann Rheum Dis 58:164–168

    Article  PubMed  CAS  Google Scholar 

  • McKone EF, Shao J, Frangolias DD, Keener CL, Shephard CA, Farin FM, Tonelli MR, Pare PD, Sandford AJ, Aitken ML, Kavanagh TJ (2006) Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease. Am J Respir Crit Care Med 174:415–419

    Article  PubMed  CAS  Google Scholar 

  • Mekus F, Ballmann M, Bronsveld I, Bijman J, Veeze H, Tummler B (2000) Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res 3:277–293

    Article  PubMed  CAS  Google Scholar 

  • Mickle JE, Cutting GR (2000) Genotype-phenotype relationships in cystic fibrosis. Med Clin North Am 84:597–607

    Article  PubMed  CAS  Google Scholar 

  • Molteni A, Moulder JE, Cohen EF, Ward WF, Fish BL, Taylor JM, Wolfe LF, Brizio-Molteni L, Veno P (2000) Control of radiation-induced pneumopathy and lung fibrosis by angiotensin-converting enzyme inhibitors and an angiotensin II type 1 receptor blocker. Int J Radiat Biol 76:523–532

    Article  PubMed  CAS  Google Scholar 

  • Moss RB, Bocian RC, Hsu YP, Dong YJ, Kemna M, Wei T, Gardner P (1996) Reduced IL-10 secretion by CD4+ T lymphocytes expressing mutant cystic fibrosis transmembrane conductance regulator (CFTR). Clin Exp Immunol 106:374–388

    Article  PubMed  CAS  Google Scholar 

  • Moss RB, Mayer-Hamblett N, Wagener J, Daines C, Hale K, Ahrens R, Gibson RL, Anderson P, Retsch-Bogart G, Nasr SZ, Noth I, Waltz D, Zeitlin P, Ramsey B, Starko K (2005) Randomized, double-blind, placebo-controlled, dose-escalating study of aerolized interferon gamma-1b in patients with mild to moderate cystic fibrosis lung disease. Pediatr Pulmonol 39:209–218

    Article  PubMed  Google Scholar 

  • Noone PG, Hamblett N, Accurso F, Aitken ML, Boyle M, Dovey M, Gibson R, Johnson C, Kellerman D, Konstan MW, Milgram L, Mundahl J, Retsch-Bogort G, Rodman D, Williams-Warren J, Wilmott RW, Zeitlin P, Ramsey B; Cystic Fibrosis Therapeutics Development Research Group (2001) Safety of aerosolized INS 365 in patients with mild to moderate cystic fibrosis: results of a phase I multi-center study. Pediatr Pulmonol 32:122–128

    Article  PubMed  CAS  Google Scholar 

  • Osika E, Cavaillon JM, Chadelat K, Boule M, Fitting C, Tournier G, Clement A (1999) Distinct sputum cytokine profiles in cystic fibrosis and other chronic inflammatory airway disease. Eur Respir J 14:339–346

    Article  PubMed  CAS  Google Scholar 

  • Plant BJ, Gallagher CG, Bucala R, Baugh JA, Chappell S, Morgan L, O’Connor CM, Morgan K, Donnelly SC (2005) Cystic fibrosis, disease severity and a macrophage migration inhibitory factor polymorphism. Am J Respir Crit Care Med 172:1412–1415

    Article  PubMed  Google Scholar 

  • Poller W, Faber JP, Weidinger S, Tief K, Scholz S, Fischer M, Olek K, Kirchgesser M, Heidtmann HH (1993) A leucine-to-proline substitution causes a defective alpha 1-antichymotrypsin allele associated with familial obstructive lung disease. Genomics 17:740–743

    Article  PubMed  CAS  Google Scholar 

  • Ratjen F, Mellies U, Starke K, Brunar H, Laliberte TW, Widman R, Molina L, Grasemann H (2005) An evaluation of the safety and tolerability of multiple rising dose regimens of aerosolized Moli1901 in patients with cystic fibrosis. Pediatr Pulmonol Suppl [abstract] 28:265

    Google Scholar 

  • Rigat B, Hubert C, Alhene-Gelas F, Cambien F, Corvol P, Soubrier F (1990) An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 86:1343–1346

    Article  PubMed  CAS  Google Scholar 

  • Robinson M, Daviskas E, Eberl S, Baker J, Chan HK, Anderson SD, Bye PT (1999) The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 14:678–685

    Article  PubMed  CAS  Google Scholar 

  • Roilides E, Dimitriadou A, Kadiltsoglou I, Sein T, Karpouzas J, Pizzo PA, Walsh TJ (1997) IL-10 exerts suppressive and enhancing effects on antifungal activity of mononuclear phagocytes against Aspergillus fumigatus. J Immunol 158:322–329

    PubMed  CAS  Google Scholar 

  • Roomans GM (2003) Pharmacological approaches to correcting the ion transport defect in cystic fibrosis. Am J Respir Med 2:413–431

    PubMed  CAS  Google Scholar 

  • Roum JH, Borok Z, McElvaney NG, Grimes GJ, Bokser AD, Buhl R, Crystal RG (1999) Glutathione aerosol suppresses lung epithelial surface inflammatory cell-derived oxidants in cystic fibrosis. J Appl Physiol 87:438–443

    PubMed  CAS  Google Scholar 

  • Schwarz KB, Rosensweig J, Sharma S, Jones L, Durant M, Potter C, Narkewicz MR (2003) Plasma markers of platelet activation in cystic fibrosis liver and lung disease. J Pediatr Gastroenterol Nutr 37:187–191

    Article  PubMed  CAS  Google Scholar 

  • Stanke F, Becker T, Cuppens H, Kumar V, Cassiman JJ, Jansen S, Radojkovic D, Siebert B, Yarden J, Ussery DW, Wienker TF, Tummler B (2006) The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis. Hum Genet 119:331–343

    Article  PubMed  CAS  Google Scholar 

  • Storm van’s Gravesande K, Wechsler ME, Grasemann H, Silverman ES, Le L, Palmer LJ, Drazen JM (2003) Association of a missense mutation in the NOS3 gene with exhaled nitric oxide levels. Am J Respir Crit Care Med 168:228–231

    Article  PubMed  Google Scholar 

  • Sullivan KJ, Kissoon N, Duckworth LJ, Sandler E, Freeman B, Bayne E, Sylvester JE, Lima JJ (2001) Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Respir Crit Care Med 164:2186–2190

    PubMed  CAS  Google Scholar 

  • Summerfield JA, Ryder S, Sumiya M, Thursz M, Gorchein A, Monteil MA, Turner MW (1995) Mannose binding protein gene mutations associated with unusual and severe infections in adults. Lancet 345:886–889

    Article  PubMed  CAS  Google Scholar 

  • Suter S, Schaad UB, Tegner H, Ohlsson K, Desgrandchamps D, Waldvogel FA (1986) Levels of free granulocyte elastase in bronchial secretions from patients with cystic fibrosis: effect of antimicrobial treatment against Pseudomonas aeruginosa. J Infect Dis 153:902–909

    PubMed  CAS  Google Scholar 

  • Suthanthiran M, Li B, Song JO, Ding R, Sharma VK, Schwartz JE, August P (2000) Transforming growth factor-beta 1 hyperexpression in African-American hypertensives: a novel mediator of hypertension and/or target organ damage. Proc Natl Acad Sci USA 97:3479–3484

    Article  PubMed  CAS  Google Scholar 

  • Tagore A, Gonsalkorale WM, Pravica V, Hajeer AH, McMahon R, Whorwell PJ, Sinnott PJ, Hutchinson IV (1999) Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. Tissue Antigens 54:386–390

    Article  PubMed  CAS  Google Scholar 

  • Taouil K, Hinnrasky J, Hologne C, Corlieu P, Klossek JM, Puchelle E (2003) Stimulation of beta 2-adrenergic receptor increases cystic fibrosis transmembrane conductance regulator expression in human airway epithelial cells through a camp/protein kinase A-independent pathway. J Biol Chem 278:17320–17327

    Article  PubMed  CAS  Google Scholar 

  • Texereau J, Marullo S, Hubert D, Coste J, Dusser DJ, Dall’Ava-Santucci J, Dinh-Xuan AT (2004) Nitric oxide synthase 1 as a potential modifier gene of decline in lung function in patients with cystic fibrosis. Thorax 59:156–158

    Article  PubMed  CAS  Google Scholar 

  • The Cystic Fibrosis Genetic Analysis Consortium (1994) Population variation of common cystic fibrosis mutations. Hum Mutat 4:167–177

    Article  Google Scholar 

  • Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV (1997) An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet 24:1–8

    PubMed  CAS  Google Scholar 

  • Uhal BD, Gidea C, Bargout R, Bifero A, Ibarra-Sunga O, Papp M, Flynn K, Filippatos G (1998) Captopril inhibits apoptosis in human lung epithelial cells: a potential antifibrotic mechanism. Am J Physiol 275:L1013–L1017

    PubMed  CAS  Google Scholar 

  • Verkman AS, Matthay MA, Song Y (2000) Aquaporin water channels and lung physiology. Am J Physiol Lung Cell Mol Physiol 278:L867–L879

    PubMed  CAS  Google Scholar 

  • Vester U, Kranz B, Zimmermann S, Büscher R, Hoyer PF (2005) The response to cyclophosphamide in steroid-sensitive nephrotic syndrome is influenced by polymorphic expression of glutathion-S-transferases-M1 and -P1. Pediatr Nephrol 20:478–481

    Article  PubMed  Google Scholar 

  • Wechsler ME, Grasemann H, Deykin A, Silverman EK, Yandava CN, Israel E, Wand M, Drazen JM (2000) Exhaled nitric oxide in patients with asthma: association with NOS1 genotype. Am J Respir Crit Care Med 162:2043–2047

    PubMed  CAS  Google Scholar 

  • Wechsler ME, Lehman E, Lazarus SC, Lemanske RF Jr, Boushey HA, Deykin A, Fahy JV, Sorkness CA, Chinchilli VM, Craig TJ, DiMango E, Kraft M, Leone F, Martin RJ, Peters SP, Szefler SJ, Liu W, Israel E; National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network (2006) Beta-adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 173:519–526

    Article  PubMed  CAS  Google Scholar 

  • WHO/ICF (1994) Therapeutic approaches for cystic fibrosis: memorandum from a joint WHO/ICF (M) A meeting. Bull World Health Organ 72:341–352

    Google Scholar 

  • Wilkinson J 4th, Clapper ML (1997) Detoxication enzymes and chemoprevention. Proc Soc Exp Biol Med 216:192–200

    PubMed  CAS  Google Scholar 

  • Wooldridge JL, Deutsch GH, Sontag MK, Osberg I, Chase DR, Silkoff PE, Wagener JS, Abman SH, Accurso FJ (2004) NO pathway in CF and non-CF children. Pediatr Pulmonol 37:338–350

    Article  PubMed  Google Scholar 

  • Wu L, Chau J, Young RP, Pokorny V, Mills GD, Hopkins R, McLean L, Black PN (2004) Transforming growth factor-beta1 genotype and susceptibility to chronic obstructive pulmonary disease. Thorax 59:126–129

    Article  PubMed  CAS  Google Scholar 

  • Yamada Y, Miyauchi A, Goto J, Takagi Y, Okuizumi H, Kanematsu M, Hase M, Takai H, Harada A, Ikeda K (1998) Association of a polymorphism of the transforming growth factor-beta1 gene with genetic susceptibility to osteoporosis in postmenopausal Japanese women. J Bone Miner Res 13:1569–1576

    Article  PubMed  CAS  Google Scholar 

  • Yarden J, Radojkovic D, De Boeck K, Macek M Jr, Zemkova D, Vavrova V, Vlietinck R, Cassiman JJ, Cuppens H (2005) Association of tumour necrosis factor alpha variants with the CF pulmonary phenotype. Thorax 60:320–325

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University Children’s Hospital, Hufelandstrasse 55, 45122, Essen, Germany

    Rainer Büscher

  2. Division of Respiratory Medicine, The Hospital for Sick Children, Toronto, Ontario, M5G 1X8, Canada

    Hartmut Grasemann

Authors
  1. Rainer Büscher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hartmut Grasemann
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rainer Büscher.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Büscher, R., Grasemann, H. Disease modifying genes in cystic fibrosis: therapeutic option or one-way road?. Naunyn-Schmied Arch Pharmacol 374, 65–77 (2006). https://doi.org/10.1007/s00210-006-0101-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00210-006-0101-2

Keywords

Search

Navigation